RU2007124638A - Препараты непафенака для местного применения - Google Patents
Препараты непафенака для местного применения Download PDFInfo
- Publication number
- RU2007124638A RU2007124638A RU2007124638/15A RU2007124638A RU2007124638A RU 2007124638 A RU2007124638 A RU 2007124638A RU 2007124638/15 A RU2007124638/15 A RU 2007124638/15A RU 2007124638 A RU2007124638 A RU 2007124638A RU 2007124638 A RU2007124638 A RU 2007124638A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- composition according
- agent
- mannitol
- group
- Prior art date
Links
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 title claims 2
- 229960001002 nepafenac Drugs 0.000 title claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 5
- 229930195725 Mannitol Natural products 0.000 claims 5
- 239000000594 mannitol Substances 0.000 claims 5
- 235000010355 mannitol Nutrition 0.000 claims 5
- 229920002125 Sokalan® Polymers 0.000 claims 4
- 229960001631 carbomer Drugs 0.000 claims 4
- 239000003755 preservative agent Substances 0.000 claims 4
- 230000002335 preservative effect Effects 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 229960000686 benzalkonium chloride Drugs 0.000 claims 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical group [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 3
- 239000002738 chelating agent Substances 0.000 claims 3
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical group O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims 3
- 229960004224 tyloxapol Drugs 0.000 claims 3
- 229920001664 tyloxapol Polymers 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 claims 2
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
- RFIMISVNSAUMBU-UHFFFAOYSA-N 2-(hydroxymethyl)-2-(prop-2-enoxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC=C RFIMISVNSAUMBU-UHFFFAOYSA-N 0.000 claims 1
- 239000004155 Chlorine dioxide Substances 0.000 claims 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 claims 1
- 229940086737 allyl sucrose Drugs 0.000 claims 1
- 229960001716 benzalkonium Drugs 0.000 claims 1
- -1 benzalkonium halides Chemical class 0.000 claims 1
- 235000019398 chlorine dioxide Nutrition 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229910001510 metal chloride Inorganic materials 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000008213 purified water Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims 1
- 229960005066 trisodium edetate Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63256204P | 2004-12-02 | 2004-12-02 | |
| US60/632,562 | 2004-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007124638A true RU2007124638A (ru) | 2009-01-10 |
Family
ID=35848959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007124638/15A RU2007124638A (ru) | 2004-12-02 | 2005-12-02 | Препараты непафенака для местного применения |
Country Status (23)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI358290B (en) | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
| SI1885336T1 (sl) * | 2005-05-10 | 2009-08-31 | Alcon Inc | Suspenzijske formulacije, ki obsegajo aktivno sestavino, poloksamerni ali meroksapolni surfaktant in glikol, in njihova uporaba za pripravo zdravila za zdravljenje oftalmičnih motenj |
| AU2006244245B2 (en) * | 2005-05-10 | 2010-11-18 | Alcon, Inc. | Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders |
| TW200812575A (en) * | 2006-04-28 | 2008-03-16 | Alcon Inc | Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye |
| US20080057022A1 (en) * | 2006-08-30 | 2008-03-06 | Erning Xia | Ophthalmic Pharmaceutical Compositions and Uses Thereof |
| CN101754748A (zh) * | 2007-05-24 | 2010-06-23 | 阿西克斯医疗公司 | 治疗干眼症的制剂和方法 |
| TWI531362B (zh) * | 2008-07-21 | 2016-05-01 | 艾爾康股份有限公司 | 具有治療劑遞送能力之眼科裝置 |
| TW201023912A (en) * | 2008-12-05 | 2010-07-01 | Alcon Res Ltd | Pharmaceutical suspension |
| US8912236B2 (en) * | 2009-03-03 | 2014-12-16 | Alcon Research, Ltd. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye |
| CN105362221A (zh) * | 2009-03-03 | 2016-03-02 | 爱尔康研究有限公司 | 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物 |
| HUE038821T2 (hu) | 2009-12-03 | 2018-11-28 | Novartis Ag | Karboxivinil polimert tartalmazó nanorészecske szuszpenziók |
| US9544143B2 (en) | 2010-03-03 | 2017-01-10 | Duo Security, Inc. | System and method of notifying mobile devices to complete transactions |
| US9532222B2 (en) | 2010-03-03 | 2016-12-27 | Duo Security, Inc. | System and method of notifying mobile devices to complete transactions after additional agent verification |
| US9467463B2 (en) | 2011-09-02 | 2016-10-11 | Duo Security, Inc. | System and method for assessing vulnerability of a mobile device |
| CN104114154A (zh) * | 2011-12-16 | 2014-10-22 | 阿勒根公司 | 包含聚乙烯基己内酰胺-聚乙酸乙烯酯-聚乙二醇接枝共聚物(Soluplus)的眼用组合物 |
| WO2014207769A1 (en) | 2013-06-27 | 2014-12-31 | Mylan Laboratories Ltd | Process for the preparation of nepafenac |
| CN104490861A (zh) * | 2014-11-21 | 2015-04-08 | 三明欣茂药业有限公司 | 一种缓释型奈帕芬胺眼用制剂 |
| HUE048564T2 (hu) | 2015-01-26 | 2020-08-28 | Bausch & Lomb | Szemészeti szuszpenzió készítmény |
| US9930060B2 (en) | 2015-06-01 | 2018-03-27 | Duo Security, Inc. | Method for enforcing endpoint health standards |
| CN107024550A (zh) * | 2016-12-21 | 2017-08-08 | 广州仁恒医药科技股份有限公司 | 奈帕芬胺眼用药物组合物的质控方法 |
| CN106963730A (zh) * | 2016-12-22 | 2017-07-21 | 广州仁恒医药科技股份有限公司 | 高度稳定的奈帕芬胺眼用药物组合物 |
| US10412113B2 (en) | 2017-12-08 | 2019-09-10 | Duo Security, Inc. | Systems and methods for intelligently configuring computer security |
| US11658962B2 (en) | 2018-12-07 | 2023-05-23 | Cisco Technology, Inc. | Systems and methods of push-based verification of a transaction |
| IT201900000561A1 (it) * | 2019-01-14 | 2020-07-14 | Medivis S R L | Formulazioni topiche oftalmiche chimicamente e fisicamente stabili a base di Nepafenac |
| JP6994061B2 (ja) * | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| CN114272207B (zh) * | 2022-01-21 | 2023-04-11 | 山东诺明康药物研究院有限公司 | 一种纳米晶混悬滴眼液及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1226344A (cg-RX-API-DMAC7.html) | 1967-07-31 | 1971-03-24 | ||
| CH577461A5 (cg-RX-API-DMAC7.html) | 1975-08-13 | 1976-07-15 | Robins Co Inc A H | |
| US4313949A (en) | 1979-09-26 | 1982-02-02 | A. H. Robins Company, Inc. | Method of producing an inhibitory effect on blood platelet aggregation |
| US4254146A (en) | 1979-10-18 | 1981-03-03 | A. H. Robins Company, Inc. | 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters |
| IL61945A (en) | 1980-02-19 | 1984-09-30 | Robins Co Inc A H | 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them |
| US4503073A (en) | 1981-01-07 | 1985-03-05 | A. H. Robins Company, Incorporated | 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids |
| IL64724A0 (en) | 1981-02-17 | 1982-03-31 | Robins Co Inc A H | 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them |
| US4568695A (en) | 1983-12-07 | 1986-02-04 | A. H. Robins Company, Incorporated | 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor |
| US4851443A (en) | 1985-03-14 | 1989-07-25 | Smith Kline Dauelsberg, Gmbh | Carboxylic acid amides, compositions and medical use thereof |
| EP0195582B1 (en) | 1985-03-14 | 1990-01-24 | SMITH KLINE DAUELSBERG GmbH | 5-aminosalicylic acid derivatives of non-steroidal antiinflammatory acids |
| US4683242A (en) | 1985-10-28 | 1987-07-28 | A. H. Robins Company, Incorporated | Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters |
| DK406686D0 (da) | 1986-08-26 | 1986-08-26 | Hans Bundgaard | Carboxylsyrederivater |
| US4910225A (en) | 1988-01-27 | 1990-03-20 | Senju Pharmaceutical Co., Ltd. | Locally administrable therapeutic composition for inflammatory disease |
| US5461081A (en) | 1989-09-28 | 1995-10-24 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| US5624893A (en) | 1993-10-14 | 1997-04-29 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation |
| US5475034A (en) | 1994-06-06 | 1995-12-12 | Alcon Laboratories, Inc. | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
| US6066671A (en) * | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
| AR030346A1 (es) * | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico |
| AR030345A1 (es) * | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes relacionados con angiogenesis |
| PL373787A1 (en) * | 2002-05-03 | 2005-09-19 | Alcon Inc. | Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac |
| WO2004064828A1 (ja) | 2003-01-21 | 2004-08-05 | Senju Pharmaceutical Co., Ltd. | ２−アミノ−３−(４−ブロモベンゾイル)フェニル酢酸含有水性液剤 |
| TWI358290B (en) | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
-
2005
- 2005-11-23 TW TW094141182A patent/TWI358290B/zh not_active IP Right Cessation
- 2005-11-28 AR ARP050104964A patent/AR052252A1/es not_active Application Discontinuation
- 2005-11-29 UY UY29238A patent/UY29238A1/es not_active Application Discontinuation
- 2005-12-02 WO PCT/US2005/043545 patent/WO2006060618A2/en not_active Ceased
- 2005-12-02 CA CA2586807A patent/CA2586807C/en not_active Expired - Lifetime
- 2005-12-02 BR BRPI0518904-7A patent/BRPI0518904B1/pt active IP Right Grant
- 2005-12-02 ES ES05825662T patent/ES2348249T3/es not_active Expired - Lifetime
- 2005-12-02 AU AU2005311738A patent/AU2005311738B2/en not_active Expired
- 2005-12-02 US US11/292,484 patent/US7834059B2/en active Active
- 2005-12-02 DE DE602005022756T patent/DE602005022756D1/de not_active Expired - Lifetime
- 2005-12-02 KR KR1020077012413A patent/KR101289661B1/ko not_active Expired - Fee Related
- 2005-12-02 RU RU2007124638/15A patent/RU2007124638A/ru unknown
- 2005-12-02 JP JP2007544521A patent/JP4968844B2/ja not_active Expired - Lifetime
- 2005-12-02 AT AT05825662T patent/ATE476200T1/de active
- 2005-12-02 SI SI200531107T patent/SI1819362T1/sl unknown
- 2005-12-02 EP EP05825662A patent/EP1819362B1/en not_active Expired - Lifetime
- 2005-12-02 ZA ZA200704763A patent/ZA200704763B/xx unknown
- 2005-12-02 MX MX2007006558A patent/MX2007006558A/es active IP Right Grant
- 2005-12-02 PL PL05825662T patent/PL1819362T3/pl unknown
- 2005-12-02 PT PT05825662T patent/PT1819362E/pt unknown
- 2005-12-02 CN CNA200580041442XA patent/CN101068573A/zh active Pending
- 2005-12-02 DK DK05825662.9T patent/DK1819362T3/da active
-
2010
- 2010-09-14 CY CY20101100830T patent/CY1110780T1/el unknown
- 2010-09-23 US US12/888,631 patent/US8071648B2/en not_active Expired - Lifetime
-
2011
- 2011-10-05 US US13/253,648 patent/US8324281B2/en not_active Expired - Lifetime
- 2011-11-25 JP JP2011257966A patent/JP2012041368A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8324281B2 (en) | Topical nepafenac formulations | |
| JP2008521926A5 (cg-RX-API-DMAC7.html) | ||
| KR890004691A (ko) | 안과 제제물용 방부 시스템 | |
| EP1885336B1 (en) | Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders | |
| JP5244584B2 (ja) | キサンタンガムおよびブドウ糖を含有する眼科用組成物 | |
| RU2009149687A (ru) | Фармацевтические композиции и способы лечения сухих кератитов | |
| EP1906916B1 (en) | Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders | |
| RU2000122435A (ru) | Производные индола и фармацевтические композиции, включающие их | |
| US6399605B1 (en) | Ophthalmic composition comprising a beta -blocker | |
| ES2341789T3 (es) | Composiciones oftalmicas y metodos de uso de las mismas. | |
| JP2003073303A (ja) | 眼局所用液剤の清涼化作用の持続方法 | |
| FI4240364T3 (fi) | Levofloksasiinia ja ketorolaakkia sisältävä silmäkoostumus, menetelmä sen valmistamiseksi ja käyttö | |
| JP2002104959A (ja) | 眼科用組成物 | |
| KR20070059188A (ko) | 잔탄 검 및 아미노산을 함유하는 안과용 조성물 | |
| WO2004054593A1 (en) | Ophthalmic compositions containing bile products from animal | |
| RU98102635A (ru) | Способ профилактики синдрома жировой эмболии при эндопротезировании крупных суставов | |
| PE20050297A1 (es) | Combinacion oftalmica que comprende brimonidina y timolol |